CRYO-CELL INTERNATIONAL, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9 USD | -1.42% |
|
+1.12% | +56.52% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
Weaknesses
- The company has insufficient levels of profitability.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 300 times its estimated earnings per share for the ongoing year.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart - Surperformance
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +56.52% | 72.94M | - | ||
| +19.28% | 84.56B | C+ | ||
| -26.95% | 72.41B | B- | ||
| +4.58% | 27.73B | C+ | ||
| -7.35% | 17.75B | B | ||
| -0.46% | 17.11B | A- | ||
| +4.69% | 16.03B | A- | ||
| +8.14% | 13.72B | B- | ||
| +69.96% | 13.07B | C- | ||
| +6.59% | 12.91B | A- |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
- Stock Market
- Equities
- CCEL Stock
- Ratings Cryo-Cell International, Inc.
